Cancer immunotherapy has gained a lot of interest over the past few years due to the success of immune checkpoint inhibitors in treating cancer (1, 2). Immune checkpoint inhibitors, such as monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), have been shown to increase survival of patients with advanced cancers (1, 2). These in...

Bispecific antibodies (BsAbs) have been developed, with one antigen-binding site coordinated against the CD3 receptor (which activates cytotoxic T lymphocytes) and other specific antigens found on cancer cells (CD19, CD20, CD33, CD123, HER2, epithelial cell adhesion molecule [EpCAM], BCMA, CEA, others) [1].

background : a transrectal ultrasound-guided prostate biopsy is currently the gold standard procedure to detect prostatic adenocarcinoma. there is little information on the clinical utility of this technique for the detection of prostate adenocarcinoma in men with suspected prostate cancer in pakistan. this study seeks to determine the frequency of prostatic adenocarcinoma by using a transrecta...

Dendritic cells (DCs) are specialized antigen-presenting in humans and animals that provide antigen-specific T-cell immunity the body. It also establishes a linkage between innate adaptive immune responses. Various studies have shown malignancies or cancer may impair DCs effector functions. now become new molecular target for treatment of cancer. Modified matured could be novel biological modif...

Antibodies that block immune regulatory checkpoints (programmed cell death 1, PD-1 and cytotoxic T-lymphocyte-associated antigen 4, CTLA-4) to mobilise immunity have shown unprecedented clinical efficacy against cancer, demonstrating the importance of antigen-specific tumour recognition. Despite this, many patients still fail benefit from these treatments additional approaches are being sought....

PURPOSE Prostate specific antigen velocity 2.0 ng/ml per year or greater in the year before prostate cancer diagnosis is associated with cancer specific survival following radical prostatectomy and radiation therapy. We evaluated the relationship between prediagnosis prostate specific antigen velocity and cancer progression following primary radiation therapy. MATERIALS AND METHODS We analyze...

We investigated the potential value of prostate-specific antigen half-life (PSAHL) and decreasing velocity (PSAVd) to predict progression-free survival (PFS) and overall survival (OS) in Chinese patients with prostate cancer. A total of 153 patients treated with hormonal therapy were included in the study. Of these, 78 patients progressed to hormone-refractory prostate cancer (HRPC) and 24 pati...